Cheryl Scott

CDMO capacity is poised to meet growing viral vector needs despite manufacturing challenges.

Process-related impurities in biomanufacturing pose risks, but methods for detection and strategies for controlling contaminants ensure drug stability, safety, and efficacy.

Explore the evolution of antibody-drug conjugates (ADCs) from first to fourth generation, highlighting advancements in linkers, targeting agents, and payload efficiency.

Gain insights on method development for safety and characterization, potency bioassays, process validation, and protein concentration measurements.

BioProcess International October 2024: From the Editor.

CRL and Wheeler Bio announced a partnership “to help clients expedite their drug development journey from discovery and CMC development to manufacturing” of antibody-based biotherapeutics.

BDO USA brought leaders from up-and-coming biopharmaceutical companies to examine “make or buy” decision-making for manufacturing of advanced therapies.

Cell-line authentication is critical to cell-line development (CLD), and processes must start with the right material.

Technology advancements in digitalization, manufacturing technologies, in genetic engineering are transforming biopharmaceutical development worldwide.

Learn about the benefits of process intensification in biomanufacturing for improving affordability and access to biologic therapies and technical discussions from BioProcess International Europe.